

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------------|----------------------------|---|---|--|
| Hematology | | | | |
| Sickle cell disease | Histone deacetylase (HDAC) | <p>A study in humans suggests that the HDAC inhibitor panobinostat may be useful for treating sickle cell disease. Increasing fetal hemoglobin levels is the primary means of treating sickle cell disease.</p> <p>Analysis of blood samples from Hodgkin's lymphoma patients treated with panobinostat showed that fetal hemoglobin levels doubled from pretreatment levels. Next steps include a clinical trial of HDAC inhibitor Zolinza vorinostat in sickle cell patients.</p> <p>Novartis AG's panobinostat (LBH589) is in Phase II testing to treat Hodgkin's lymphoma.</p> <p>Merck & Co. Inc. markets Zolinza vorinostat (suberoylanilide hydroxamic acid) to treat cutaneous T cell lymphoma (CTCL).</p> <p>SciBX 3(27); doi:10.1038/scibx.2010.829 Published online July 15, 2010</p> | Work unpatented; licensing status undisclosed | <p>Bradner, J.E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 28, 2010; doi:10.1073/pnas.1006774107</p> <p>Contact: Benjamin L. Ebert, Broad Institute of MIT and Harvard, Cambridge, Mass. e-mail: bebert@partners.org</p> <p>Contact: Todd R. Golub, same affiliation as above e-mail: golub@broadinstitute.org</p> <p>Contact: Stuart L. Schreiber, same affiliation as above e-mail: stuart_schreiber@harvard.edu</p> |